CClinicalTrials.gg
RecruitingNCT06182683OPTICARE-CADUpdated Sep 30, 2026

Concurrent OCT and FFR-guided PCI in CAD

An interventional study of optical coherence tomography and fractional flow reserve and Coronary angiography in Coronary Artery Disease, Image and Atheroscleroses, Coronary, sponsored by Korea University Guro Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Korea University Guro Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The present study is a prospective randomized clinical trial aimed to compare the therapeutic strategy of angiography-guided versus concurrent OCT/FFR-guided intervention in patients with coronary artery disease.

Read the detailed description

Most previous clinical trials have assessed various interventional strategies guided by intravascular imaging (intravascular imaging-guided PCI), fractional flow reserve (FFR-guided PCI), or conventional angiography (angiography-guided PCI) to compare differences in treatment outcomes. Until now, it remains unclear whether optimizing procedures based on both intravascular imaging and fractional flow reserve indices would lead to improved treatment outcomes compared to PCI guided solely by conventional angiography. Moreover, there are no studies comparing a treatment strategy that combines optical coherence tomography (OCT) and FFR to angiography-guided procedures. Hence, this study aims to compare the clinical effectiveness and therapeutic impact of concurrent guidance using FFR and OCT in patients undergoing coronary artery stent implantation, as compared to procedures guided solely by conventional angiography.

02

Conditions studied

  • Coronary Artery Disease
  • Image
  • Atheroscleroses, Coronary

Keywords

  • Optical coherence tomography
  • Fractional flow reserve
  • Angiography
  • Coronary artery disease
  • Percutaneous coronary intervention
  • Drug-eluting stent
03

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age greater than 19 years old
  2. Patients undergoing coronary stent implantation for stable angina or acute coronary syndrome
  3. Patients provided on informed consent

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a history of increased bleeding tendencies or hematologic disorders
  2. Presented with refractory cardiogenic shock
  3. Individuals with a history of stent thrombosis
  4. Expected life expectancy of less than 1 year
  5. Left ventricular ejection fraction (LVEF) ≥ 20%
  6. Women who are breastfeeding, pregnant, or planning to become pregnant
  7. Deemed unsuitable for participation by the investigator
  8. Patients unwilling to participate in the clinical trial
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Active comparator
    Angiography-guided PCI group

    This group of patients are intended to undergo PCI with conventional angiography-guidance. Procedural optimization determined by angiographic assessment.

    Diagnostic Test: Coronary angiography

  • Experimental
    Concurrent OCT/FFR-guided PCI group

    This group of patients are intended to undergo PCI with concurrent OCT/FFR-guidance. Procedural optimization determined by OCT and FFR assessment.

    Diagnostic Test: optical coherence tomography and fractional flow reserve · Diagnostic Test: Coronary angiography

Interventions

  • Diagnostic testoptical coherence tomography and fractional flow reserve

    The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.

  • Diagnostic testCoronary angiography

    The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography

05

What researchers measure

Primary outcomes

  1. Rate of target vessel failure (TVF)

    a composite endpoint of cardiac death, target vessel-related non-fatal myocardial infarction, clinically driven-target vessel revascularization

    Time frame: 1-year

Secondary outcomes

  1. Rate of all-cause mortality

    cardiac and non-cardiac death

    Time frame: 1-year

  2. Rate of any myocardial infarction (MI)

    myocardial infarction due to target vessel and non-target vessel failure

    Time frame: 1-year

  3. Rate of clinically-driven target vessel revascularization (TVR)

    clinically-driven target vessel revascularization

    Time frame: 1-year

  4. Rate of any revascularization

    clinically-driven target lesion and non-target lesion revascularization

    Time frame: 1-year

  5. Rate of stent thrombosis (acute, subacute, late, very late)

    stent thrombosis based on presenting time after the index procedure

    Time frame: 1-year

  6. Rate of BARC-defined bleeding

    clinically-relevant bleeding event based on BARC classification

    Time frame: 1-year

Other outcomes

  1. FFR optimization rate

    1\) Post-PCI FFR ≥ 0.90, or 2) Post-PCI FFR (LAD) ≥ 0.82, or 3) Post-PCI FFR (non-LAD) ≥ 0.88, 4) Stent-segment ΔFFR ≤0.05

    Time frame: Immediately after index procedure

  2. OCT optimization rate

    1\) Post-PCI MSA ≥ 4.5 mm2, and 2) Post-PCI expansion ≥ 80%

    Time frame: Immediately after index procedure

06

Study locations

1 of 1 sites recruiting
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
    Recruiting
07

References and documents

Publications

  • Johnson TW, Raber L, di Mario C, Bourantas C, Jia H, Mattesini A, Gonzalo N, de la Torre Hernandez JM, Prati F, Koskinas K, Joner M, Radu MD, Erlinge D, Regar E, Kunadian V, Maehara A, Byrne RA, Capodanno D, Akasaka T, Wijns W, Mintz GS, Guagliumi G. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2019 Aug 14;40(31):2566-2584. doi: 10.1093/eurheartj/ehz332. PubMed 31112213 ↗
  • Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039. Epub 2021 Dec 9. PubMed 34882436 ↗
  • Collison D, Didagelos M, Aetesam-Ur-Rahman M, Copt S, McDade R, McCartney P, Ford TJ, McClure J, Lindsay M, Shaukat A, Rocchiccioli P, Brogan R, Watkins S, McEntegart M, Good R, Robertson K, O'Boyle P, Davie A, Khan A, Hood S, Eteiba H, Berry C, Oldroyd KG. Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). Eur Heart J. 2021 Dec 1;42(45):4656-4668. doi: 10.1093/eurheartj/ehab449. PubMed 34279606 ↗

Individual participant data

Plan to share: Undecided — Individual participant data will be available to qualified researchers only upon reasonable request and appropriate proposal to the principal investigator.

08

Registry details

Key details

Study ID
NCT06182683
Lead sponsor
Korea University Guro Hospital
Responsible party
Kang Dong Oh (Assistant Professor, Korea University Guro Hospital) — Principal investigator
First posted
Dec 27, 2023
Start date
Nov 30, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Dong Oh Kang, MD, PhD
Contact
gelly9@naver.com
82-2-2626-3184
Dong Oh Kang, MD, PhD
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion